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Seza Gulec, MD, FACS
Florida International University Herbert Wertheim College of Medicine, Departments of Surgery and Nuclear Medicine, Miami, USA
The Art and Science of Thyroid Surgery in the Age of Genomics: 
100 years after Theodor Kocher
Genomik Çağında Tiroid Cerrahi Sanat ve Bilimi: Theodor Kocher’den 100 Sene Sonra
Abstract
Cancer is a disorder of the genome. The thyroid cancer genome is being decoded. Recent studies have identified a mutation 
or a genetic alteration in 95% of thyroid cancers. The National Cancer Institute initiated the Cancer Genome Atlas project in 
2006 to catalogue genetic mutations associated with cancer, using genome sequencing and bioinformatics. The project has 
expanded to carry out genomic characterization and sequence analysis of thyroid cancer. The concept of risk stratification 
based on traditional parameters will soon vacate their role for clear molecular markers of non-invasive/focal, invasive/
metastatic and systemic stages/phases of neoplastic disorder. A refined classification scheme based on genomics and its 
phenotypic expressions will accurately reflect the biologic differences between the different morphologic definitions we use 
today. Tumor differentiation/de-differentiation, and clinical behavior of an individual cancer will be defined by molecular 
markers, in addition to standard morpho-pathology. Empiricism in science of medicine and surgery has acquired a new 
method for testing the appropriate treatment for individual patients; that is molecular pathology, governed by genomics. The 
technology is present and rapidly evolving. The surgeons will determine the extent of interventions with molecular evidence 
and guidance.
Keywords: Genomics, thyroid cancer, thyroidectomy, radioactive iodine, beta knife
Öz
Tiroid cerrahisinin bilimsel temelleri Theodor Kocher tarafından tanımlandı. Bu ustayı 100 yıl önce uğurladık. Tirod kanseri 
cerrahisi ve tiroid kanseri hastalarının tedavisi ile tartışmalar süregelmektedir. Konunun mihengi açıkçası ilk aşama cerrahi 
tedavinin boyutudur. Cerrahi tedaviyi izleyen kısa ve uzun dönemde uygulanabilecek tedaviler, yararlanılabilecek tetkik 
ve görüntüleme yöntemleri de ilk cerrahi tedavinin çerçevesiyle alakalıdır. Amerikan Tiroid Birliği’nin 2015 basımı tedavi 
kılavuzu dahil olmak üzere, geleneksel olarak tiroid kanserinin klinik değerlendirmesi morfolojik öğelere dayalı yapılır. Tümör 
büyüklüğü, histolojik varyantlar ve hasta yaşı kriterleri cerrahi ve cerrahi sonrası girişimlerin boyutunu belirler. Kanser genomu 
projesi kapsamında tiroid kanseri genom profili aydınlanmaya başladı. Hala birçok bilinmeyen olmakla birlikte bu konuda 
bilgi birikimimiz hızla artıyor. İnce iğne biyopsisi materyalinde hastaların kromozom değişiklikleri ve nokta mutasyonları tespit 
edilebilmekte, bu genomik değişikliklerin biyolojik anlamları araştırılabiliyor. Bu teknoloji hızla teşhis ve tedavi yönlendirilmesinde 
kullanıma giriyor. Bundan böyle tedavi seçimlerinde genomik kılavuz ve yönlendirme kullanılacak. Bu makale cerrahi sanatının 
mahir ustalarını ve cerrahi bilimindeki genomik devrimi selamlıyor.
Anahtar kelimeler: Genomik, tiroid kanseri, tiroidektomi, radyoaktif iyot, beta bıçak
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2Milestones
Theodor Kocher died 100 years ago in 1917. Kocher is 
considered the father of thyroid surgery (Figure 1).
He received the 1909 Nobel Prize in Physiology or Medicine 
for his work in the physiology, pathology and surgery of 
the thyroid. A few weeks before his death, at the age of 
76, he made his final appearance before the Swiss Surgical 
Congress, reviewing his entire thyroid surgery experience. 
Kocher reported on approximately 5.000 operations with 
a mortality of about 0.5%. When he started his work in 
the 1870s, thyroid surgery was a high-risk procedure, with 
an estimated mortality of 75% in 1872. Thyroid operations 
were prohibited by the Academy of Medicine in France at 
that time. Kocher was appointed to the Chair of Surgery in 
Berne, Switzerland, in 1872, at the age of 31, and began his 
influential work in thyroid surgery and medicine. His most 
acclaimed achievement, his surgical technique, was marked 
by meticulous care in dissecting and ligating blood vessels, 
and precise dissection within the thyroid capsule (1). William 
Halsted’s impression on Kocher’s surgical technique was/
is quite remarkable. Halsted described Kocher’s technique 
as “neat and precise, operating in a relatively bloodless 
manner, scrupulously removing the entire thyroid gland 
doing little damage outside its capsule” (2). Kocher was 
the first to describe the devastating complication(s) of total 
extirpation of the thyroid gland. He also recognized the 
underlying pathophysiologic changes in a diseased gland. 
This was, in a sense, a “molecular vision.” He intuitively 
contemplated that the growth of goiter nodules was an 
early determined event in altered thyroid physiology, and 
that the abnormal thyroid tissue was the source of a goiter 
recurrence. He conceived the notion of autonomously 
growing, focally distributed clusters of follicular cells in 
nodular goiter. He, thus, advocated a total thyroidectomy 
rather than selective removal of all thyroid nodules. Kocher 
had realized that the so-called “subtotal” thyroidectomy, 
leaving behind naturally growth-prone tissue, would lead to 
goiter recurrence. The concept was called “Innere Chirurgie” 
(internal surgery), a scientific surgical philosophy based on 
biological considerations. This was the beginning of a new 
epoch. The leading minds were Kocher in Berne, Halsted 
in Baltimore, and Mikulicz (coined the term) in Krakau (3).
Despite impressive discoveries in surgical anatomy and 
physiology, the onco-biology of neoplasia and the clinico-
pathologic characteristics of cancer were poorly understood 
at Kocher’s time. Although Kocher had significant studies on 
malignant tumors of the thyroid gland, the modern science 
for cancer surgery was developed by William Halsted, who 
championed a radical treatment approach for breast cancer. 
Halsted’s idea was based on the premise that cancer had 
a linear, step-wise growth fate and had to be be treated 
with total extirpation of the organ along with its lymphatic 
drainage network. This was believed to be necessary for 
cure, and was adapted by many prominent surgeons. 
This classic rationalistic philosophy in surgery dominated 
the surgical world for years. Similarly, thyroid surgery for 
cancer in the early post-Kocher era, called for an “en-block 
resection” or “conventional radical neck dissection,” which 
usually sacrificed the sternocleidomastoid muscle, internal 
jugular vein, often the accessory nerve and sometimes the 
marginal mandibular branch of the facial nerve. This was 
all justified in the name of “cure. The core problem with 
the rationalistic logical flow is the potential/possible flaw 
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The extirpation of the thyroid gland typifies, 
perhaps better than any operation, the 
supreme triumph of the surgeon’s art. A 
feat which today can be accomplished by 
any competent operator without danger of 
mishap and which was conceived more than 
one thousand years ago might appear an 
unlikely competitor for a place in surgery so 
exalted. 
William Stewart Halsted
Figure 1. Theodor Kocher
3in the original hypothesis. The entire chain of thoughts/
deductions, then, may lead to incorrect conclusions 
(a-priori error). The outcomes, however, need to be tested 
independently. (post-priori validation). This is the essence 
of evidence-based, data-driving scientific methodology”. 
George “Barney” Crile Jr. should be credited as the first 
to challenge the radical thought process and action. He 
was one of the first surgeons ever to promote the idea 
that “the less surgery the better,” and he campaigned 
vigorously for the abandonment of the radical operations. 
His ideas on thyroid cancer surgery, and later breast cancer 
surgery, were briskly opposed at the time, but eventually 
succeeded (4). The new surgical vision was reluctantly, 
but progressively accepted by the surgical community over 
time, and has since, shaped the evolution of the philosophy 
of surgical treatment. 
Mid-century brought in a major innovation in the 
management of thyroid cancer, the radioactive iodine 
(RAI) treatment. First used by Samuel Seidlin (5), and 
established as a fortitude by Bierwaltes (6), RAI became 
an invaluable theranostic agent. The role for RAI in 
the management of metastatic differentiated thyroid 
cancer (DTC) became indisputable. Its utilization post-
operatively, however, is still a matter of debate. As a guide 
to perplexed; RAI treatment is given in 3 distinct settings 
with distinct clinical indications (intents). 1) Ablation of 
the remnant 2) Adjuvant treatment for residual disease or 
occult metastatic disease 3) Therapy for known metastatic 
disease. The term “ablation” specifically refers to first-line 
RAI treatment following total surgical thyroidectomy. The 
specific target of this treatment is normal residual thyroid 
tissue- the remnant. The objectives of ablation are three-
folds a) Ablation eradicates all the functioning thyroid 
tissue. Thereby, thyroglobulin (Tg) becomes a highly 
specific tumor marker. This simply facilitates the post-op 
long-term follow-up. b) Ablation wipes out all focal normal 
thyroid tissue left in-situ by the surgeon to avoid injury to 
laryngeal nerves and parathyroid glands. From surgical 
standpoint these small clusters of normal tissue remnants 
are inconsequential, however, they appear as focal areas 
of RAI uptake on future whole body imaging studies and 
can easily be called as metastatic disease. Eradication of 
these potential source of misdiagnosis, when surgeon 
to imager communication is still on-line, is important. 
c) Post-ablation whole-body scan is an excellent extent 
of disease evaluation tool. When the post-operative RAI 
treatment is contemplated with an adjuvant intent, in 
addition to the ablation objectives, RAI is aimed to target 
residual disease or occult metastatic disease. When 
the intent is adjuvant treatment, the risk stratification 
becomes important in the selection of administered 
activity of I-131. For remnant ablation purposes only, the 
risk stratification has no bearing. The therapeutic effect 
of I-131 works through the beta particles, thus, it should 
be referred as “beta-knife.” Complete thyroidectomy, in 
the strictest sense is only possible with surgical (cold steel 
knife) thyroidectomy, followed by I-131 ablation (beta 
knife) (Table 1).
The second half of the 20th century also witnessed the 
birth of neo-empiricism in the acquisition and application of 
scientific knowledge in medicine. The established dogmas 
for radical surgical treatments were challenged, asking for 
proof of efficacy based on outcome data. The new paradigm 
was most palpable in the management of breast cancer 
and thyroid cancer. The radical versus conservative surgery 
argument was relatively easy to settle for breast cancer. 
Bernard Fisher in the US and Umberto Veronesi in Italy ran 
parallel trials resulting in clear demonstration of equivalency 
of lesser surgery over radical operations. The problem with 
thyroid cancer, however, remained unsettled. DTC was/is a 
more indolent cancer with a much more protracted course. 
Clinical trials with required statistical power were very difficult 
to perform. The lack of definitive clinical trials unleashed a 
never-ending controversy: Total thyroidectomy versus less 
than total thyroidectomy. A new, rather ambiguous, lexis for 
such operations entered into common use. Sub-total, near-
total thyroidectomy terms subsisted. At least for the sake 
of clarification of the nomenclature, there should only be 
two standard defining operations: Total thyroidectomy and 
lobectomy. Total thyroidectomy is defined as the safe removal 
of the thyroid gland with oncologically clean margins. If/
when eradication of all functioning thyroid tissue is the end 
point, a cold steel knife is followed by the beta-knife.
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Table 1. Radioactive iodine ablation objectives
RAI treatment intent Target Objectives
Ablation (First-line) Remnant 1) Increase specificity of Tg monitoring,
2) Complete post-surgical staging
3) Identify/clear ambiguous foci of uptake
Adjuvant treatment (First-line) 1) Remnant,
2) Residual disease,
3) Occult metastatic disease
1) Ablation objectives,
2) Disease control
Therapy (Second-line) 1) Recurrent disease,
2) Metastatic disease
1) Disease control
RAI: Radioactive iodine, Tg: Thyroglobulin
4The Equipoise
An equipoise is a genuine disagreement among the experts 
as to the optimal therapeutic approach in the management 
of a particular condition. A true equipoise exists in the initial 
treatment of DTC. There are two camps, represented by 
two diametrically opposing philosophical thoughts. There 
are those aggressively favor/defend the strategy of total 
thyroidectomy with radioiodine ablation and periodic Tg 
screening for “biochemical evidence of recurrence”. On the 
opposite direction there are those taking a conservative stand 
and prefer/defend performing thyroid lobectomy, when the 
tumor is small and limited to one lobe of the gland. This 
stance would automatically rule out post-surgical ablation as 
well as “affect” the utility of Tg screening. This approach 
relies more on clinical and ultrasound findings for “clinical 
evidence of recurrence.” It is a true equipoise, as there is 
genuine uncertainty in the expert medical community over 
which approach is more beneficial. The option of lobectomy 
(pertaining to tumors measuring 1cm or less), was proposed 
in the 2009 American Thyroid Association (ATA) guidelines 
(7). It became the recommended option for small tumors 
in its 2015 edition (8). A more progressive conservatism is 
endorsed in the 2010 version of the Japanese guidelines for 
the treatment of thyroid tumors. In the Japanese guidelines, 
the indications for a lobectomy were extended to tumors as 
large as 4 cm, if they are limited to one lobe of the thyroid 
with little or no extra-capsular invasion and no gross lymph 
node involvement. As for papillary carcinoma less than 1cm, 
some Japanese surgeons are proposing that observation 
without surgical intervention may be sufficient (9).
It would have been easier to compose a narrative if the history 
of thyroid surgery was a linear progression from a radical 
operation towards a lesser one. The story, however, is more 
confounded, partly due to the particular characteristics of the 
disease and perhaps more so due to entrenched positions of 
opinionated surgeons and oncologists, the very definition of 
equipoise. All respectable institutions, and the thought leaders 
in the field have made their contributions to the controversy 
(10,11,12,13). Equipoise has become the standard of care in 
the initial surgical treatment of thyroid cancer.
Authors on both sides of the debate have pointed out that 
not all papillary carcinomas are equally indolent. Some 
grow rapidly and progress more aggressively than others 
often without obvious histological differences. Histological 
variations such as the tall cell variant and columnar cell variant 
have been identified, but many unusually malignant strains 
cannot be morphologically distinguished as being different 
from other examples of papillary carcinoma. Certain well-
DTC will go on to have an aggressive course. They cannot 
be histopathologically differentiated from those with typical 
indolent course There appears not to have an exact way of 
identifying those relatively infrequent differentiated cancers 
that are destined to have a more malignant course. Despite 
the significant progress in molecular pathology, the clinical 
risk factors are currently the only stratification guide used 
in thyroid cancer diagnosis and management. Proponents of 
total thyroidectomy insist that the increase in complications is 
minimal in the hands of an experienced surgeon. Proponents 
of lobectomy point out that only one recurrent laryngeal 
nerve is at risk when only one lobe of the thyroid is being 
resected, thus the theoretical risk of nerve palsy is halved. 
Disagreement over the merits of prophylactic central node 
dissection has been argued in a similar context. Experience 
suggests that the incidence of surgical complications may 
not solely be dependent on the proficiency of the surgeon, 
but also the extent of surgical procedure performed. So the 
debate goes on, “equipoetically”.
The American Thyroid Association Guidelines, 
2015
The 2015 ATA guidelines is a 133 page document written in a 
dissertation format. The rationale for each recommendation 
was discussed, in detail, in a scholarly fashion. The section 
on operative approach for a biopsy diagnostic for follicular 
cell-derived malignancy (B7, Recommendation 35) defines 
three categories. 
The guideline committee states that in properly selected 
low to intermediate risk patients, the extent of initial 
thyroid surgery probably has little impact on disease 
specific survival. While recurrence rates can be quite low in 
properly selected patients, it is likely that the lowest rates of 
recurrence during long term follow-up would be associated 
with a total thyroidectomy. However, since salvage therapy 
would be quite effective in the few patients that recur after 
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The Japanese Guidelines, 2010
A) It is beyond dispute that patients with the following 
characteristics are regarded as high-risk; tumor size 
>5 cm, lymph node metastasis >3 cm, lymph node 
metastasis extending to the internal jugular vein, 
carotid artery, major nerves such as recurrent laryngeal 
nerve, and prevertebral fascia, multiple and intensely 
swollen lymph node metastasis, extrathyroidal 
extension to the trachea and esophageal mucosa and 
distant metastasis at diagnosis. Total thyroidectomy 
is recommended for patients having one or more of 
these characteristics (p.108)
B) Other patients are classified as a “gray-zone”, but 
in these patients total thyroidectomy is recommended 
if the tumor size is >4 cm, and clinical node metastasis 
is detected (regardless of whether it is N1a or N1b) 
(p.108)
C) Although further studies with larger patient 
numbers and longer follow-up times are required, 
observation without immediate surgery for papillary 
microcarcinoma without metastasis or invasion can be 
considered a reasonable option (p.121).
5thyroid lobectomy, a conservative management approach 
to up front surgery accepting a slightly higher risk of loco-
regional recurrence is an acceptable management strategy.
The guideline committee further stated that a more 
selective use of RAI coupled with a greater reliance on neck 
ultrasound and serial serum Tg measurements for detection 
of recurrent disease is likely to significantly decrease the 
mandate for total thyroidectomies in low and intermediate 
risk patients done solely to facilitate RAI remnant ablation 
and follow-up. Near-total or total thyroidectomy is 
necessary if the overall strategy is to include RAI therapy 
postoperatively, and thus is recommended if the primary 
thyroid carcinoma is >4 cm, there is gross extra-thyroidal 
extension, or regional or distant metastases are present. 
For tumors that are between 1 and 4 cm in size, either a 
bilateral thyroidectomy (total or near-total) or a unilateral 
procedure (thyroid lobectomy) may serve as the surgical 
platform for an overall treatment plan. Older age (>45 
years), contralateral thyroid nodules, a personal history of 
radiation therapy to the head and neck, or familial DTC 
may be criteria for recommending a bilateral procedure. 
This could help the plans for RAI therapy, facilitate follow-
up strategies, and also may address suspicions of bilateral 
disease (8). This conclusion returns us back to square one. 
The accurate identification of individual patients who would 
benefit from a limited intervention versus those who would 
require the full artillery in hand remains challenged. Clearly, 
a statistically insignificant, but clinically very important group 
of outliers of risk categories defined using standard criteria 
does exist. Particularly for DTC, morphology (or size)-alone 
only partially explains the full onco-biology of the tumor.
Risk Stratification and Staging of Thyroid Cancer
All cancers present as either localized or at an advanced/
metastatic stage, as does the thyroid cancer. The existing 
paradigm equates metastatic stage to a systemic disorder. 
The established staging system has become ingrained in 
our culture. Some of the seemingly “self-evident” concepts 
require revision. The extent of disease has been defined 
by the TNM system, and stages have been determined 
by outcome statistics. For DTC, patients younger than 45, 
are assigned to stage II despite the presence of remote 
metastatic disease (Table 2). A 2016 consensus report 
based on a review of 9484 patients from 10 institutions 
proposed a change in the cutoff age in the current American 
Joint Committee on Cancer/Union for International Cancer 
Control staging system from 45 years to 55 years. This 
change is estimated to lead to a down-staging of 12% of 
patients, and would improve the statistical validity of the 
existing model. Such a change may be clinically relevant 
for thousands of patients worldwide by preventing over-
staging of patients with low-risk disease while providing a 
more realistic estimate of prognosis for those who remain 
high risk (14). The current paradigm has been inadequate 
to resolve the growing controversies. There does not 
appear to be a magic age cut-off that dicotomizes the 
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Table 2. Staging of thyroid cancer
Papillary and follicular thyroid cancer (age <45 y)
Stage T N M
I Any T Any N M0
II Any T Any N MI
Papillary and follicular thyroid cancer (age ≥45 y)
Stage T N M
I T1 N0 M0
II T2 N0 M0
III T3 N0 M0
IVA
T1-3 N1a M0
T4a N1b M0
IVB T4b Any N M0
IVC Any T Any N M1
American Thyroid Association 2015 Guidelines
A) For patients with thyroid cancer >4 cm, or with 
gross extra-thyroidal extension (clinical T4), or clinically 
apparent metastatic disease to nodes (clinical N1) or 
distant sites (clinical M1), the initial surgical procedure 
should include a near-total or total thyroidectomy 
and gross removal of all primary tumor unless there 
are contraindications to this procedure. (Strong 
Recommendation, Moderate-quality evidence),
B) For patients with thyroid cancer >1 cm and <4 
cm without extra-thyroidal extension, and without 
clinical evidence of any lymph node metastases (cN0), 
the initial surgical procedure can be either a bilateral 
procedure (near-total or total thyroidectomy) or a 
unilateral procedure (lobectomy). Thyroid lobectomy 
alone may be sufficient initial treatment for low risk 
papillary and follicular carcinomas; however, the 
treatment team may choose total thyroidectomy to 
enable RAI therapy or to enhance follow-up based upon 
disease features and/or patient preferences. (Strong 
Recommendation, Moderate-quality evidence),
C) If surgery is chosen for patients with thyroid 
cancer <1 cm without extra-thyroidal extension 
and cN0, the initial surgical procedure should be a 
thyroid lobectomy unless there are clear indications 
to remove the contralateral lobe. Thyroid lobectomy 
alone is sufficient treatment for small, unifocal, intra-
thyroidal carcinomas in the absence of prior head 
and neck irradiation, familial thyroid carcinoma, or 
clinically detectable cervical nodal metastases (Strong 
Recommendation, Moderate-quality evidence).
6patients into distinct risk categories. A remote metastatic 
disease may not be the ultimate grave sign. There may 
be another “phase” in cancer, besides the T, N, and M 
extensions, that has not been factored-in current disease 
state definitions. There could be a metabolic switch 
converting cancer into a “systemic disorder”. There may 
be a difference between a widespread disease and a 
systemic disorder, which would define/explore the cancer-
host metabolic interactions beyond mere expansion of 
the cancer compartment. The metabolic and catabolic 
changes associated with this change in phase have not 
been identified. The road to fatality could be a phase 
change during any given stage of cancer expansion. The 
phase change could well be occurring in M0 disease or, 
adversely develop at a seemingly early stage. The cellular/
subcellular dynamics of a true systemic disorder remain 
undefined. The predicative molecular signatures of the 
phase change has not been firmly defined. Ultimately, the 
molecular profiling of individual cancers would be gauging 
the credence of our knives. The foreseeable paradigm 
change awaits the maturation of the genomics revolution.
The Age of Genomics
Cancer is a disorder of the genome. 
The thyroid cancer genome is being decoded. Recent 
studies have identified a mutation or a genetic alteration 
in 95% of thyroid cancers. The National Cancer Institute 
initiated the Cancer Genome Atlas (TCGA) project in 2006 
to catalogue genetic mutations associated with cancer, 
using genome sequencing and bioinformatics. The project 
has expanded to carry out genomic characterization and 
sequence analysis of a multitude of cancers, including 
thyroid cancer. Techniques involve gene expression 
profiling, copy number variation profiling, single nucleotide 
pleomorphism genotyping, genome wide DNA methylation 
profiling, microRNA profiling, and exon sequencing of at 
least 1,200 genes. TCGA is able to sequence the entire 
genomes of tumors, including at least 6,000 candidate 
genes and microRNA sequences. 
The Integrated Genomic Characterization of Papillary 
Thyroid Carcinoma (IGCPTC) study, the first systematic, 
large scale and robust genomic analysis of thyroid cancer, 
was published in October 2014 (15). The IGCPTC study 
demonstrated the role of somatic genetic “alterations.” The 
driving somatic genetic alterations included SSNVs, indels, 
or fusions, in the mitogen-activated protein kinases (MAPK) 
and PI3K pathways in PTC. The relatively low overall density 
of somatic mutations was concluded to be the biological 
basis for the indolent clinical behavior of PTC. It is evident 
that the mutations and alterations are functions of time to 
accompany the aging process. The prognostic importance 
of age is a continuous variable, not determined by a cut-
off value. New driver mutations were identified in PTC, 
either entirely novel (EIF1AX), or novel alterations of known 
drivers (RET, BRAF and ALK fusions) (Figure 1). As a result 
of these discoveries, the “dark matter” of the PTC genome 
has been reduced substantially from ∼25% to less than 4%, 
which will have profound consequences for preoperative 
cancer diagnosis of thyroid nodules as well as for surgical 
and post-surgical treatment strategies. Molecular testing for 
mutation hotspots, rearrangements, and gene expression 
using fine-needle aspiration specimens has become an 
Seza Gulec. Thyroid Surgery in the Age of Genomics Mol Imaging Radionucl Ther 2017;26(Suppl 1):1-9
Cancer is a disorder of the genome. The complete 
genetic information of an organism is referred to 
as genome. In all-encompassing terms, the genome 
involves the genes (coding and the non-coding 
sequences of the DNA), RNA(s), the process of 
transcription and translation and their regulations. The 
concept of regulation involves the genetic constituents 
such as enhancer, promoter, transcription factors (TF), 
RNA polymerase and mechanisms such as epigenetics. 
Cancer is a complex expression of multiple genetic 
and epigenetic alterations. There is an initiating 
transformational mutational event, then a multitude 
of genetic aberrations compose a cancer phenotype. 
All cells throughout the body bear the same coding 
sequence, yet, tissues and organs have distinct 
morphology and functions. Normal tissue/organ 
differentiation is simply a function of selective reading 
of the genome by different cell types, most vivid in the 
developing embryo. Cancer is a distinct differentiation, 
or neo-differentiation, or dedifferentiation, in 
reference to the normal tissue morphology/function. 
As cells enter into a constitutive act of replication or 
repeated cycles of growth and division, the central 
hallmark of cancer, they also begin to assume distinct 
phenotypes. This is the process of neo-differentiation. 
The cells undergoing the neo-differentiation process 
become committed to form different type of tissue 
rather than the mature, conformal normal tissue. The 
genome reading has a new translation.
The gene expression is modulated by “the switches”. 
The orchestration of gene expression by “the switches” 
involves multiple elements; The enhancer, a non-coding 
DNA sequence where the TF bind. The binding of the 
TF is arbitrated by a group of mediator proteins. The 
enhancer sequence is located some distance upstream 
of the promotor region, another non-coding DNA 
sequence, to which RNA polymerase binds. All these 
elements are also product of different set of coding 
genes (subject to mutational changes). Moreover, if 
a particular switch is deemed a compartment, the 
intra-compartmental interactions are subject to the 
chemical conformations altered by acetylation or 
methylation reactions which are not mutational, but 
referred to as “epigenetic” changes.
7effective diagnostic tool to more precisely select patients 
for an appropriate surgical procedure. Molecular testing 
surely would reduce the number of thyroidectomies done 
for benign nodules and tumors (16,17), and could guide 
determine the extent of initial surgical procedure (i.e., 
lobectomy versus total thyroidectomy). Beyond the driver 
mutations, it was also discovered that several individual key 
genes [CHEK2, ATM, and Telomerase reverse transcriptase 
(TERT)] and sets of functionally related genes (chromatin 
remodeling) with alterations or expression patterns in 
microRNA (miR-21 and miR-146b) define clinically-relevant 
subclasses and may contribute to loss of differentiation and 
tumor progression.
The IGCPTC study demonstrated striking signaling 
differences in RAS- and BRAFV600E-driven PTCs. In 
particular, BVL-PTCs signal preferentially through MAPK 
while RL-PTCs signal through both MAPK and PI3K. The 
relative simplicity of the PTC genome, with dominant 
mutually exclusive driving events, together with the large 
cohort and comprehensive data analyzed in this study 
have led to clearly dissect these signaling differences. The 
overreaching conclusion of the IGCPTC study was that RL-
PTCs and BVL-PTCs are fundamentally different in their 
genetic, epigenetic, and proteomic profiles. Based on 
the strength of the multidimensional genomic findings, 
a clinico-pathologic reclassification of follicular-derived 
thyroid lesions would be imperative (15).
The impact of different genomic markers on outcomes 
opened a new field of controversy. Conflicting results 
with BRAF (+) tumors have been reported for the past 
10 years. An increasing number of studies, which include 
meta-analyses, demonstrated an association between 
the BRAF status and aggressive tumor behavior. Other 
studies, however, have failed to confirm this data, and 
this has resulted in uncertainty about the prognostic 
value of BRAF mutations in PTC (18,19) It has become 
clear that multiple genetic alterations contribute to 
form an individual tumor phenotype and biology. A 
progressive genomic instability leads to first functional, 
then morphologic dedifferentiation. TERT promoter 
mutations have been observed in 5% to 25% of DTC, 
and it’s been reported that TERT promoter mutations 
contribute to aggressive behavior in DTC (20,21,22). 
These mutations have a significantly higher prevalence 
in aggressive thyroid tumor types such as widely invasive 
oncocytic carcinomas, poorly differentiated carcinomas, 
and anaplastic thyroid carcinomas (ATC) (23). Similarly, 
TP53 mutations are prevalent in advanced tumors with 
a higher recurrence (24). A co-occurrence of multiple 
mutations may define a more aggressive subgroup of 
DTC (25).
The next-generation sequencing technology allows high 
out-put genomic analysis. An innovative assay in thyroid 
cancer ThyroSeq® - was developed for targeted mutation 
detection by next generation sequencing technology in 
fine needle aspiration and tissue samples. ThyroSeq v.2 
next generation sequencing panel offers simultaneous 
sequencing and detection in >1000 hotspots of 14 thyroid 
cancer-related genes and for 42 types of gene fusions 
known to occur in thyroid cancer (Table 3) (26). ThyroSeq is 
being increasingly used to further narrow the indeterminate 
category defined by cytology for thyroid nodules. From 
a surgical perspective, obviously this provides prognostic 
and predictive information as it relates to determination of 
surgical strategy. Both the genomic analysis technology and 
the data collection for the cancer genome atlas are rapidly 
developing. 
Although we have sequenced the cancer genome 
extensively, and have identified a number of driver 
and passenger mutations, we are yet far from having 
a map of the full genomic alterations involved in the 
onco-pathogenesis of thyroid cancer (Figure 2). We 
are, though, capable of patterning the phenotypic 
expressions in terms of profiling. Individual tumor 
morphology, function and biology are compound results 
of mutational changes, and selective activation and/or 
deactivation of gene switches. Eventually, the cancer 
morphology, or architectural neo-differentiation will 
be understood and defined in terms of sets of genes 
that are expressed (transcribed) in neoplastic tissues. 
Perhaps the “papillary thyroid cancer” assignment based 
on morphology, its intricate variations, and perplexing 
functional and prognostic associations will be replaced 
by gene expression profiles, mathematical abstractions, 
with clear indications as to its biologic meaning. We 
will, though, continue to refer to the morphology as 
part of its complete profile, not a sole indicator of its 
prognosis and treatment options. This will also pave the 
road to rational treatment actions. The concept of risk 
stratification based on traditional parameters will soon 
vacate their role for clear molecular markers of non-
invasive/focal, invasive/metastatic and systemic stages/
phases of neoplastic disorder. 
Truly local/indolent tumors could easily be addressed 
with less invasive techniques such as Laser ablation and 
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Table 3. ThyroSeq v2 panel
Gene mutations 
(DNA)
Gene fusions 
(RNA)
Gene expression (RNA)
BRAF RET RET PGK1 Pan-cell
NRAS TSHR PPARG KRT7
Thyroid cell
HRAS AKT1 NTRK1 TG
KRAS TP53 NTRK3 TTF1
PIK3CA GNAS BRAF NIS
PTEN CTNNB1 ALK Calcitonin MTC
TERT EIF1AX PTH Parathyroid
KRT20 Metastatic
8radiofrequency ablation, at the most by lobectomy. On the 
other hand when a potential for metastatic development 
is identified, regardless of the tumor size or patient’s 
age, the most aggressive approach including complete 
thyroidectomy (surgical total thyroidectomy followed by 
beta-knife ablation) will be employed. We will not feel 
inadequate to explain to an unfortunate patient why 
his/her small, supposed to be indolent tumor is taking a 
fatal course. We will not record those cases as statistical 
misfits. Patient-specific treatment protocols will prevail. A 
refined classification scheme based on genomics and its 
phenotypic expressions will accurately reflect the biologic 
differences between the different morphologic definitions 
we use today. Tumor differentiation/de-differentiation, and 
clinical behavior of an individual cancer will be defined 
by molecular markers, in addition to standard morpho-
pathology. Empiricism in science of medicine and surgery 
has acquired a new method for testing the appropriate 
treatment for individual patients; that is molecular 
pathology, governed by genomics. The technology is 
present and rapidly evolving. The surgeons will determine 
the extent of interventions with molecular evidence and 
guidance.
The translation of cancer genomics data into clinical 
insights will elevate oncology to the next level and usher 
in a new era in understanding, diagnosing and treating 
cancer. The new evidence in “evidence-based medicine” 
is the genomic data.
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In god we trust, 
All others must bring data.
William Edward Deming
Figure 2. Main mutation mechanisms: Point mutations and chromosome rearrangements
Adapted from Nikiforov YE, Diagnostic pathology and molecular genetics of the thyroid, 2009
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